Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 126

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 9C
Chunk 126
---
 Alliances and Partnerships based in New York, and as the head of the Oncology Therapeutic Area Global
Medical and Outcomes Group, including the U.S. oncology medical business. Through his multiple roles at Pfizer, Dr. Eagle delivered significant
business growth and was involved in multiple strategic acquisitions and divestitures. In addition, while at Pfizer, Dr. Eagle oversaw
extensive oncology clinical trial programs, multiple regulatory and payer approvals across Pfizer’s oncology portfolio, health
outcomes assessments and scientific collaborations with key global research organizations like the National Cancer Institute (NCI), and
the European Organization for Research and Treatment of Cancer (EORTC), and led worldwide development of several compounds including
celecoxib, aromasin, irinotecan, dalteparin and ozagomicin. Dr. Eagle currently serves as a member of the board of directors and chair
of the Science and Policy Committee of Pierian Biosciences, a privately held life sciences company. Dr. Eagle attended Medical School
at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in
Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney and was granted
Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA). After his
training, Dr. Eagle performed basic research at the Royal Prince of Wales hospital to develop a new monoclonal antibody to inhibit platelets
before moving into the pharmaceutical industry. Dr. Eagle’s qualifications to sit on our board of directors include his long and
successful career in the international pharmaceutical industry, his senior executive experience in areas such as business growth, strategic
alliances and mergers and acquisition transactions, his experience as a member of both public and private company boards in the healthcare
and life science industries, and his wealth of oncology 

Edward
MacPherson joined our company as a director in March 2024. Mr. MacPherson currently serves as Chief Growth Officer for Power
Digital, an industry leading digital marketing agency. Prior to joining Power Digital, from May 2016 to December 2023, he served as CEO
and Head of Growth for Endrock Growth & Analytics, a company he founded and sold to Power Digital. Prior to founding Endrock Growth
& Analytics, Mr. MacPherson held senior marketing and leadership positions at